IN THE CLAIMS:

Cancel claims 37 and 40.

Amend claims 35, 36, 42, 43 and 48-51 as follows:

35. (Twice amended) A pharmaceutical formulation for parenteral administration comprising [a] an optically pure solid state Na^+ [, Li^+ or K^+] salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5,-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole as active ingredient, and a pharmaceutically acceptable carrier.

36. (Twice amended) A pharmaceutical formulation for parenteral administration comprising an [a sterile] injection solution comprising [a] an optically pure solid state Na^+ [, Li^+ or K^+] salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5,-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole as active ingredient, and a pharmaceutically acceptable carrier in the form of a pharmaceutically acceptable solvent having a volume sufficient to effect a solution having a concentration of 0.1 to 10% by weight of the active ingredient.

42. (Twice amended) A method of inhibiting gastric acid secretion comprising the parenteral administration to a mammal including man in need of such treatment of a pharmaceutical formulation comprising a therapeutically effective amount of [a] an optically pure solid state Na^+ [, Li^+ or K^+] salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5,-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole and a pharmaceutically acceptable carrier.

32

47. (Twice amended) A method for the treatment of gastrointestinal inflammatory disease comprising the parenteral administration to a mammal including man in need of such treatment of a pharmaceutical formulation comprising a therapeutically effective amount of [a] an optically pure solid state Na^+ [, Li^+ or K^+] salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5,-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole, and a pharmaceutically acceptable carrier.

In claim 47, delete "or 45".

48. (Amended) The method according to claim 47 [42 or 43 or 45], wherein a solution with the [a] solvent carrier is prepared [effected] immediately before the administration.

49. (Amended) The method of claim 47 [42 or 43 or 45], wherein the solvent has a volume effecting a solution of a concentration of 0.1-10% by weight of the active ingredient.

51. (Amended) A method of inhibiting gastric acid secretion [for treating gastrointestinal disease] comprising injecting a mammal including man in need of such treatment with a [sterile] solution of an optically pure solid state Na^+ salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5,-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and a pharmaceutically acceptable solvent having a volume sufficient to effect a solution having a concentration of 0.1 to 10% by weight of the active ingredient [the composition according to claim 42 or 43 or 45].